Teva gets a mixed bag of PhIII data as it lines up against a (better?) Neurocrine rival for tardive dyskinesia
Four months after the FDA rejected Teva’s “breakthrough” drug SD-809 for treating chorea associated Huntington’s disease, the pharma group is back with a batch of mixed Phase III data on tardive dyskinesia, the involuntary movements associated with the degenerative disease. And once again Teva is upbeat about the results, saying the data clears the way to a new marketing pitch later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.